NASDAQ:AMLX - US03237H1014 - Common Stock
We assign a fundamental rating of 3 out of 10 to AMLX. AMLX was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AMLX as it has an excellent financial health rating, but there are worries on the profitability. AMLX is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -96.4% | ||
ROE | -111.75% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 12.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.72 | ||
Quick Ratio | 8.72 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
9.42
-0.03 (-0.32%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2019.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5 | ||
P/tB | 5 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -96.4% | ||
ROE | -111.75% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 5343.95% | ||
Cap/Sales | 8709.62% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.72 | ||
Quick Ratio | 8.72 | ||
Altman-Z | 12.24 |